Search

Your search keyword '"Buscarino M"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Buscarino M" Remove constraint Author: "Buscarino M"
18 results on '"Buscarino M"'

Search Results

2. P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer

Catalog

Books, media, physical & digital resources

3. Therapeutics

4. Bending Sensors Based on Thin Films of Semitransparent Bithiophene-Fulleropyrrolidine Bisadducts

5. Genetic Characteristics and Long-Term Follow-Up of Slovenian Patients with RPGR Retinal Dystrophy.

6. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.

7. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.

8. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

9. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

10. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.

11. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

12. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

13. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

14. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

15. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

16. Delusional parasitosis in a female treated with mixed amphetamine salts: a case report and literature review.

17. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

18. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.